ProJenX

ProJenX is a clinical-stage biotechnology company with novel brain-penetrant targeted therapies to address debilitating brain diseases, initially focusing on amyotrophic lateral sclerosis (ALS). ProJenX was founded through a long-term research collaboration between the ALS project and researchers at Columbia University, aiming to rapidly develop and commercialize its lead therapeutic candidate, prosetin, for ALS patients.